A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment

Approximately 20% of HER2 positive breast cancer develops disease recurrence after adjuvant trastuzumab treatment. This study aimed to develop a molecular prognostic model that can reliably stratify patients by risk of developing disease recurrence. Using miRNA microarrays, nine miRNAs that differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, F., Yuan, P., Zhao, Z. T., Yang, Z., Wang, T., Zhao, J. D., Luo, Y., Ma, F., Wang, J. Y., Fan, Y., Cai, R. G., Zhang, P., Li, Q., Song, Y. M., Xu, B. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030658/
https://www.ncbi.nlm.nih.gov/pubmed/27650797
http://dx.doi.org/10.1038/srep33825
_version_ 1782454718168039424
author Du, F.
Yuan, P.
Zhao, Z. T.
Yang, Z.
Wang, T.
Zhao, J. D.
Luo, Y.
Ma, F.
Wang, J. Y.
Fan, Y.
Cai, R. G.
Zhang, P.
Li, Q.
Song, Y. M.
Xu, B. H.
author_facet Du, F.
Yuan, P.
Zhao, Z. T.
Yang, Z.
Wang, T.
Zhao, J. D.
Luo, Y.
Ma, F.
Wang, J. Y.
Fan, Y.
Cai, R. G.
Zhang, P.
Li, Q.
Song, Y. M.
Xu, B. H.
author_sort Du, F.
collection PubMed
description Approximately 20% of HER2 positive breast cancer develops disease recurrence after adjuvant trastuzumab treatment. This study aimed to develop a molecular prognostic model that can reliably stratify patients by risk of developing disease recurrence. Using miRNA microarrays, nine miRNAs that differentially expressed between the recurrent and non-recurrent patients were identified. Then, we validated the expression of these miRNAs using qRT-PCR in training set (n = 101), and generated a 2-miRNA (miR-4734 and miR-150-5p) based prognostic signature. The prognostic accuracy of this classifier was further confirmed in an internal testing set (n = 57), and an external independent testing set (n = 53). Besides, by comparing the ROC curves, we found the incorporation of this miRNA based classifier into TNM stage could improve the prognostic performance of TNM system. The results indicated the 2-miRNA based signature was a reliable prognostic biomarker for patients with HER2 positive breast cancer.
format Online
Article
Text
id pubmed-5030658
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50306582016-09-26 A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment Du, F. Yuan, P. Zhao, Z. T. Yang, Z. Wang, T. Zhao, J. D. Luo, Y. Ma, F. Wang, J. Y. Fan, Y. Cai, R. G. Zhang, P. Li, Q. Song, Y. M. Xu, B. H. Sci Rep Article Approximately 20% of HER2 positive breast cancer develops disease recurrence after adjuvant trastuzumab treatment. This study aimed to develop a molecular prognostic model that can reliably stratify patients by risk of developing disease recurrence. Using miRNA microarrays, nine miRNAs that differentially expressed between the recurrent and non-recurrent patients were identified. Then, we validated the expression of these miRNAs using qRT-PCR in training set (n = 101), and generated a 2-miRNA (miR-4734 and miR-150-5p) based prognostic signature. The prognostic accuracy of this classifier was further confirmed in an internal testing set (n = 57), and an external independent testing set (n = 53). Besides, by comparing the ROC curves, we found the incorporation of this miRNA based classifier into TNM stage could improve the prognostic performance of TNM system. The results indicated the 2-miRNA based signature was a reliable prognostic biomarker for patients with HER2 positive breast cancer. Nature Publishing Group 2016-09-21 /pmc/articles/PMC5030658/ /pubmed/27650797 http://dx.doi.org/10.1038/srep33825 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Du, F.
Yuan, P.
Zhao, Z. T.
Yang, Z.
Wang, T.
Zhao, J. D.
Luo, Y.
Ma, F.
Wang, J. Y.
Fan, Y.
Cai, R. G.
Zhang, P.
Li, Q.
Song, Y. M.
Xu, B. H.
A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
title A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
title_full A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
title_fullStr A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
title_full_unstemmed A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
title_short A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
title_sort mirna-based signature predicts development of disease recurrence in her2 positive breast cancer after adjuvant trastuzumab-based treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030658/
https://www.ncbi.nlm.nih.gov/pubmed/27650797
http://dx.doi.org/10.1038/srep33825
work_keys_str_mv AT duf amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT yuanp amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT zhaozt amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT yangz amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT wangt amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT zhaojd amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT luoy amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT maf amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT wangjy amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT fany amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT cairg amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT zhangp amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT liq amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT songym amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT xubh amirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT duf mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT yuanp mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT zhaozt mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT yangz mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT wangt mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT zhaojd mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT luoy mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT maf mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT wangjy mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT fany mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT cairg mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT zhangp mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT liq mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT songym mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment
AT xubh mirnabasedsignaturepredictsdevelopmentofdiseaserecurrenceinher2positivebreastcancerafteradjuvanttrastuzumabbasedtreatment

Ejemplares similares